Author

K. A. Gammeltoft

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

A. Offersgaard· 2 shared J. Bukh· 2 shared J. M. Gottwein· 2 shared L. V. Pham· 2 shared S. Ramirez· 2 shared U. Fahnoe· 2 shared Y. Zhou· 2 shared A. Binderup· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Offersgaard

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivJun 6, 2022

Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro

Y. Zhou, K. A. Gammeltoft, L. A. Ryberg…·J. M. Gottwein

This study identifies nirmatrelvir-resistant SARS-CoV-2 variants with high in vitro fitness and shows that remdesivir remains effective against them.

DOI 10.1126/sciadv.add7197

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivDec 2, 2020

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro

K. A. Gammeltoft, Y. Zhou, A. Galli…·J. M. Gottwein

This study evaluates the efficacy of HCV protease inhibitors against SARS-CoV-2 and their interactions with remdesivir, finding simeprevir shows synergism and is the most promising for future antiviral treatments.

DOI 10.1128/aac.02680-20

humanexperimental assay

𝕏 PostBluesky